Highest-materiality recent filing
Sabra Q2 2026 Normalized FFO $0.38; closes $599M YTD investments; reiterates guidance
Net loss $(0.10) per share; Normalized FFO $0.38; AFFO $0.39; Normalized AFFO $0.40.
Sabra raises FY 2026 Normalized FFO guidance 7% YoY; re-tenants 26 Avamere properties
Entered LOI to re-tenant all 26 Avamere properties; 22 to Cascadia, 4 to existing tenant; annual cash rent expected $53M (up ~30% from $41M).
Sabra Q1: EPS $0.16, AFFO $0.39; same-store NOI +14.4%; reiterates 2026 guidance
Net income $0.16/diluted share; FFO $0.37, Normalized FFO $0.38, AFFO $0.39, Normalized AFFO $0.39.
Sabra Q4 FFO $0.36 per share; guides 2026 Normalized FFO $1.49-1.53 midpoint up 4.9% YoY
Q4 2025 net income $0.11/diluted share; Normalized FFO $0.36; AFFO $0.37; Normalized AFFO $0.38.
Sabra Q3 2025: Normalized FFO $0.36; raises managed senior housing target to 40% of NOI
Q3 Normalized FFO $0.36 per share; AFFO $0.37; Net income $0.09 diluted.
Sabra Q2 Normalized FFO $0.37; invests $122M YTD; closes $500M term loan; updates FY guidance
Q2 Normalized FFO $0.37, Normalized AFFO $0.38, Net Income $0.27 per diluted share.
Sabra Health Care enters $500M term loan, redeems $500M 5.125% notes due 2026
Entered $500M unsecured term loan maturing July 30, 2030; accordion allows increase to $1B subject to conditions.
Sabra Health Care REIT to redeem $500M 5.125% Notes due 2026, refinance with term loan
Redemption of all $500M aggregate principal of 5.125% Senior Notes due 2026 on July 31, 2025.
Sabra Q1 FFO $0.35, AFFO $0.37; same-store senior housing NOI up 16.9% YoY
Net income $0.17/diluted share, FFO $0.36, Normalized FFO $0.35, AFFO $0.37.
Sabra CIO Talya Nevo-Hacohen to retire Dec 31, 2025; Darrin Smith to succeed Jan 1, 2026
Talya Nevo-Hacohen (EVP/CIO/Treasurer) retires Dec 31, 2025; Darrin Smith (EVP-Investments) becomes CIO Jan 1, 2026.
Sabra Q4 2024 EPS $0.19; Normalized FFO $0.35; guides 2025 Normalized FFO $1.43-$1.46
Q4 net income $0.19/diluted share; Normalized FFO $0.35; AFFO $0.36.
Sabra Q3 FFO $0.34, raises 2024 normalized FFO midpoint; $100M in acquisitions
Q3 diluted EPS $0.13; Normalized FFO $0.35; AFFO $0.36.
Sabra Q2 2024 FFO $0.35; raises 2024 guidance; acquires $76M senior housing
Net income $0.10/diluted share; Normalized FFO $0.35; AFFO $0.36 per share.
Q4 2023 Net income $0.07/sh; Normalized FFO $0.32; AFFO $0.32.
Sabra Q3 net loss $0.07, FFO $0.33; senior housing managed occupancy up 170 bps to 81.9%
Net loss per diluted share $0.07; FFO $0.33; Normalized FFO $0.33; AFFO $0.35.
Sabra Q2 FFO $0.32, dividend $0.30; occupancy gains, Medicaid rates up >5%
Q2 diluted net income $0.09; Normalized FFO $0.33; AFFO $0.33; Normalized AFFO $0.34.
Sabra Health Care REIT reports Q1 net loss $(0.04) per share, Normalized FFO $0.33
Net loss per diluted share $(0.04); Normalized FFO $0.33, AFFO $0.33.
Sabra Health Care REIT establishes $500M ATM equity offering program with forward sale agreements
Up to $500M in common stock may be sold through agents or via forward sale agreements.
Sabra Q4 2022 net loss $0.37/diluted share; Normalized FFO $0.37; dividend $0.30
Q4 2022 net loss per diluted share $(0.37); Normalized FFO $0.37, AFFO $0.34.
Sabra reports Q3 net loss of $(0.22)/share; Normalized FFO $0.36
Net loss per diluted share $(0.22); Normalized FFO $0.36 per share.
Sabra Q2 2022 FFO $0.36, Normalized AFFO $0.38; acquires $264.9M YTD; dividend $0.30/share
Q2 diluted FFO $0.36, Normalized FFO $0.39, AFFO $0.36, Normalized AFFO $0.38; net income $0.07.
Sabra Q1 Normalized AFFO $0.38 per share; dividend $0.30; skilled nursing occupancy rebounds
Q1 net income $0.18/diluted share; FFO $0.39; Normalized FFO $0.38; AFFO $0.39; Normalized AFFO $0.38.
Sabra Q4 2021 net loss $0.11/diluted share; Avamere lease restructured; Canadian JV announced
Q4 net loss of $(0.11) per diluted share; Normalized FFO $0.39; Normalized AFFO $0.37.
Sabra Q3 normalized AFFO $0.38; Avamere write-off $25.2M; reaffirms guidance
Q3 2021 normalized AFFO $0.38/diluted share; net income $0.05 includes $25.2M Avamere straight-line rent write-off.
First tranche of $325M RCA mortgage loan funded at $290M, secured by six addiction treatment centers; second $35M tranche contingent on debt service coverage.
Entered underwriting agreement Oct 12 to sell 6.8M shares at $14.40/share; underwriters exercised option for additional 1.02M shares.
Sabra Health Care REIT issues $800M of 3.200% senior notes due 2031
Net proceeds ~$784M after underwriting discounts and expenses.
Sabra Health Care REIT prices $800M 3.200% senior notes due 2031; to redeem $300M 4.800% notes
Offers $800M of 3.200% senior notes due 2031; closing expected Sep 30, 2021.
Talya Nevo-Hacohen, the Company’s Executive Vice President, Chief Investment Officer and Treasurer, has decided to retire from Sabra, effective December 31, 2025
Darrin Smith, Sabra’s Executive Vice President – Investments, is expected to assume this position effective January 1, 2026.
On November 7, 2024, Clifton J. Porter II notified the Board of Directors of Sabra Health Care REIT, Inc. (the “Company”) of his decision not to stand for reelection to the Company’s Board of Directors at the Company’s 2025 annual meeting of shareholders.
On and effective as of January 1, 2024, the Board of Directors of Sabra Health Care REIT, Inc., a Maryland corporation (“Sabra” or the “Company”), appointed Jessica Flores to serve as Executive Vice President and Chief Accounting Officer until her successor is duly elected and qualifies.
On February 7, 2022, Raymond J. Lewis notified the Board of Directors of Sabra Health Care REIT, Inc. (the “Company”) of his resignation from the Company’s Board of Directors, effective immediately.
On January 24, 2022, Ronald G. Geary notified the Board of Directors of Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) of his resignation from Sabra’s Board of Directors, effective immediately.
Harold Andrews, the Company’s Executive Vice President, Chief Financial Officer (Principal Financial Officer) and Secretary, retired from Sabra effective December 31, 2021.
On December 30, 2021, Sabra’s Board of Directors appointed Michael Costa, Sabra’s Executive Vice President – Finance and Chief Accounting Officer (Principal Accounting Officer), to succeed Mr. Andrews as the Company’s Executive Vice President, Chief Financial Officer (Principal Financial Officer) and Secretary, in each case effective January 1, 2022.
Harold Andrews, the Company’s Executive Vice President, Chief Financial Officer (Principal Financial Officer) and Secretary, has decided to retire from Sabra, effective December 31, 2021
Michael Costa, Sabra’s Executive Vice President – Finance and Chief Accounting Officer, is expected to assume each of these positions effective January 1, 2022.
Max materiality 0.80 · Median 0.60 · Most common event earnings